Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed, with no substantive content changes.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated to include new facility and location information, as well as additional resources related to various gastrointestinal diseases and neoplasms. Notably, the names of specific drugs and conditions have been revised, reflecting a shift in focus towards more current medical topics.SummaryDifference4%
- Check24 days agoChange DetectedThere are no significant changes to the web page content.SummaryDifference0.6%
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.5%
- Check38 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.0%
Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.